Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 6:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 35 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: 12-weeks of Weight Stability Clear all
Completed Phase 3 Interventional Results available

A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs

NCT03086343
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
Abatacept, Placebo for abatacept (0.9% Sodium Chloride Injection or Solution for Infusion), Upadacitinib, Placebo for upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
657 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
44
States / cities
Peoria, Arizona • Sun City, Arizona • Tucson, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2024 · Synced Sep 28, 2026, 6:56 AM EDT
Completed Phase 2 Interventional Results available

Study of Roxadustat in Non-Dialysis Chronic Kidney Disease Participants With Anemia

NCT01244763
View directory record Official record
Conditions
Chronic Kidney Disease, Anemia
Interventions
Roxadustat
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years to 75 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
35
States / cities
Mobile, Alabama • Pine Bluff, Arkansas • Azusa, California + 32 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2022 · Synced Sep 28, 2026, 6:56 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Modifying Adiposity Through Behavioral Strategies to Improve COVID-19 Rehabilitation

NCT05880108
View directory record Official record
Conditions
Post-COVID Conditions, Obesity
Interventions
12-weeks of Weight Loss, 12-weeks of Weight Stability
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Up to 80 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
2
States / cities
Baltimore, Maryland • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 28, 2026, 6:56 AM EDT
Completed Phase 2 Interventional Results available

Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis

NCT00774852
View directory record Official record
Conditions
Lupus Nephritis, Lupus Erythematosus, Systemic
Interventions
abatacept, cyclophosphamide, azathioprine, prednisone, abatacept placebo, azathioprine placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
21
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2016 · Synced Sep 28, 2026, 6:56 AM EDT
Completed Not applicable Interventional

Ischemic Conditioning to Enhance Function (I-C-FUN) in Children With Cerebral Palsy

NCT04598711
View directory record Official record
Conditions
Cerebral Palsy
Interventions
RLIC, Sham Conditioning, Muscle Power training, Balance training, Treadmill Training
Behavioral
Lead sponsor
East Carolina University
Other
Eligibility
6 Years to 16 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 12, 2023 · Synced Sep 28, 2026, 6:56 AM EDT
Terminated Phase 2 Interventional Results available

Pilot Study of Sleep Therapy and Biomarkers in Children With Autism Spectrum Disorders

NCT02487082
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Melatonin and Donepezil, Placebo
Drug · Other
Lead sponsor
Stony Brook University
Other
Eligibility
4 Years to 17 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced Sep 28, 2026, 6:56 AM EDT
Completed Not applicable Interventional

Effect of Group Pilates and Yoga Exercise Classes for Chronic Cervical Pain

NCT01999283
View directory record Official record
Conditions
Cervical Pain
Interventions
Yoga Group Exercise, Pilates Group Mat Exercise
Other
Lead sponsor
Wayne State University
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
4
States / cities
Bloomfield Hills, Michigan • Detroit, Michigan • Novi, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2013 · Synced Sep 28, 2026, 6:56 AM EDT
Completed Phase 1 Interventional

Developing Biomarkers of Dietary Intake

NCT01237093
View directory record Official record
Conditions
Diet Therapy, Healthy Volunteers
Interventions
1. Meat, no fish or soda, 2. Meat and soda, no fish, 3. Meat and fish, no soda, 4. Meat and fish and soda, 5. Fish, no meat or soda, 6. Fish and soda, no meat, 7. No meat, fish or soda, 8. Soda, no meat or fish
Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years · Male only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 28, 2026, 6:56 AM EDT
Active, not recruiting Phase 2 Interventional

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

NCT04743661
View directory record Official record
Conditions
Recurrent Medulloblastoma, Recurrent Ependymoma
Interventions
Irinotecan, Temozolomide, Bevacizumab, Omburtamab I-131, Liothyronine, SSKI, Dexamethasone, Antipyretic, Antihistamine, anti-emetics
Drug
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
Up to 21 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Los Angeles, California • New York, New York • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 28, 2026, 6:56 AM EDT
Completed Not applicable Interventional Results available

Strength on Wheels: A Meal Delivery and Exercise Intervention for Homebound Older Adults

NCT04087343
View directory record Official record
Conditions
Frailty
Interventions
Meals plus exercise, Meals only
Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
60 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Sep 28, 2026, 6:56 AM EDT
Not listed Early Phase 1 Interventional

Inducing Graft Tolerance in HLA Haplotype Matched Related and 3 Ag Matched Unrelated Living Donor Kidney Transplantation

NCT03292445
View directory record Official record
Conditions
Immune Tolerance
Interventions
Immune tolerance after kidney transplant, Donor blood stem cells and T cells
Procedure · Drug
Lead sponsor
Samuel Strober
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
2
States / cities
Palo Alto, California • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 16, 2020 · Synced Sep 28, 2026, 6:56 AM EDT
Not yet recruiting Phase 4 Interventional

Semaglutide in Youth With Autism Spectrum Disorder

NCT07770152
View directory record Official record
Conditions
Autism Spectrum Disorder, Obesity
Interventions
Glucagon-like peptide-1 receptor agonist：Semaglutide, Lifestyle Management (LSM) Counseling
Drug · Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Years to 18 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 28, 2026, 6:56 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors

NCT04134728
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
GSK3196165 (Otilimab), Sarilumab, Placebo to GSK3196165/ Sarilumab, csDMARDs
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
46
States / cities
Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2023 · Synced Sep 28, 2026, 6:56 AM EDT
Completed Not applicable Interventional

Smartphone Delivered In-home Cardiopulmonary Rehabilitation

NCT02791685
View directory record Official record
Conditions
Cardiovascular Disease, Coronary Artery Disease
Interventions
MULTIFIT Cardiac Rehabilitation, Movn Pulmonary Rehabilitation, Standard of Care Cardiac Rehabilitation
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Sep 28, 2026, 6:56 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease (VWD) Patients <6 Years of Age

NCT04953884
View directory record Official record
Conditions
Von Willebrand Disease
Interventions
Wilate
Drug
Lead sponsor
Octapharma
Industry
Eligibility
Up to 5 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Sep 28, 2026, 6:56 AM EDT
Completed Phase 1 Interventional

Effect of Liraglutide (Victoza) on Inflammation in Human Adipose Tissue and Blood

NCT02650206
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type II, Diabetes Mellitus, Adult-Onset, Inflammation
Interventions
Victoza (liraglutide) with dietician monitoring, Placebo with dietician monitoring
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
40 Years to 69 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2020 · Synced Sep 28, 2026, 6:56 AM EDT
Completed Phase 2 Interventional Results available

A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes

NCT02119819
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
LY2944876, Exenatide extended-release, Placebo, Metformin
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
31
States / cities
Concord, California • Fresno, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Sep 28, 2026, 6:56 AM EDT
Completed Phase 2 Interventional

Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab

NCT03126331
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma
Interventions
Nivolumab, Ipilimumab
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 17, 2024 · Synced Sep 28, 2026, 6:56 AM EDT
Completed Not applicable Interventional Results available

Effect of Whole Fruit on Glycemic Control in Adults With Type 2 Diabetes

NCT03758742
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
High-Fruit Diet
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
20 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 9, 2025 · Synced Sep 28, 2026, 6:56 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

NCT03510884
View directory record Official record
Conditions
Hypercholesterolaemia
Interventions
Alirocumab SAR236553 (REGN727), Rosuvastatin, Atorvastatin, Simvastatin, Pravastatin, Lovastatin, Fluvastatin, Ezetimibe, Cholestyramine, Nicotinic acid, Fenofibrate, Omega-3 fatty acids, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
8 Years to 17 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
5
States / cities
Boca Raton, Florida • St Louis, Missouri • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated May 5, 2023 · Synced Sep 28, 2026, 6:56 AM EDT
Active, not recruiting Early Phase 1 Interventional

Transformation of Paralysis to Stepping

NCT04105114
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Buspirone, Non-invasive Spinal Cord Stimulation, Overground stepping, Gravity Neutral Device, Body Weight Supported Treadmill Training, Rolling Walker
Drug · Device
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 28, 2026, 6:56 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Assessments of Adipogenesis, Lipid Turnover and Cellular Composition in Adipose Tissue in Response to Endurance Exercise

NCT06602141
View directory record Official record
Conditions
Obesity
Interventions
Muscle Biopsy, Adipose Biopsy, Glucose Clamp, Accelerometer, Endurance Exercise, Physical activity/ dietary habits, Heavy Water Labeling Period
Procedure · Other
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
18 Years to 45 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
2
States / cities
Orlando, Florida • Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 28, 2026, 6:56 AM EDT
Not yet recruiting Phase 2 Interventional

Clinical Trial Evaluating the Effects of Ganaxolone in Children With Autism

NCT07635862
View directory record Official record
Conditions
Autism in Children, Autistic Disorder in Children and Adolescents, Autism Spectrum Disorder
Interventions
Ganaxolone (Ztalmy), Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
5 Years to 17 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 28, 2026, 6:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

FoodRx for Obesity Treatment

NCT05635019
View directory record Official record
Conditions
Obesity, Food Insecurity
Interventions
BWL+VOUCHER, BWL+HOME, Behavioral weight loss counseling (BWL)
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 28, 2026, 6:56 AM EDT